NTPC Green Energy IPO: Will this clean energy play power your portfolio?
A deep-dive into NTPC Green Energy’s landmark Rs. 10,000 crore IPO.
NTPC Green Energy IPO: Will this clean energy play power your portfolio? Read More ยป
A deep-dive into NTPC Green Energy’s landmark Rs. 10,000 crore IPO.
NTPC Green Energy IPO: Will this clean energy play power your portfolio? Read More ยป
An in-depth look at the Swiggy IPO including, business, valuation and our final verdict!
Swiggy IPO: Should you place the order? Read More ยป
An in-depth look at Hyundai’s record breaking IPO including pros, cons and valuation!
Hyundai Motors India IPO: Should you subscribe? Read More ยป
A review of the Bajaj Housing Finance IPO. Find out if it is worth subscribing to in this research report.
Bajaj Housing Finance IPO: Should you subscribe? Read More ยป
The countryโs largest electric two wheeler (e2W) player Ola Electric is going for the biggest initial public offering (IPO) of the year, so far, aiming to raise Rs 6,146 crore. While the scale that this EV player is looking at is mind boggling, is its path to profitability without hurdles? Here’s a discussion that Vidya
Ola Electric IPO: Is it investment worthy? Read More ยป
Should you invest in the Rs. 960 crore Muthoot Microfin IPO? Find out in this detailed review.
Muthoot Microfin IPO: Should you invest? Read More ยป
The Tata Technologies IPO comes almost 2 decades after the earlier IPO from the Tata group. In this report, you will find out if you should invest in this IPO.
Tata Technologies IPO: Should you invest? Read More ยป
Episode 04 of the Prime Podcast
Podcast : Markets at all time highs, IPO season & Smallcaps Read More ยป
Mankind Pharma, which operates in the domestic pharmaceuticals space, opens its Rs 4300 core IPO today. The issue is priced at a band of Rs 1,026 – Rs 1,080 per share of face value Re.1/-.
Mankind Pharma IPO: Invest or avoid? Read More ยป
Sula Vineyards is launching an IPO worth Rs 960 crore, consisting solely of an offer for sale by investors including a 1% stake sale by the promoter. The offer for sale will result in approximately 32% of equity being sold by the selling shareholders with the promoter stake at ~28% post-issue. The issue opens on December 12 and closes on December 14. Shares are being offered at a price band of Rs.340-Rs.357 per share of face value Rs 2. This being an offer for sale, the company will not receive any funds from the issue.
IPO Review: Should you take a sip of the Sula Vineyards IPO? Read More ยป
The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research services before onboarding. History, Present business and Background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services. Terms and conditions of Research Services: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Analyst never guarantees the returns on the recommendation provided. Investor shall take note that Investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The Research Analyst shall not be responsible for any loss to the Investors. Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made there under against the Research Analyst relating to Research Analyst services. Details of its associates: No associates. Disclosures with respect to Research and Recommendations Services: The Research Analyst or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise. Research Analyst or its directors or its employee or its associates have not received any compensation from the company which is subject matter of recommendation. Research Analyst or its directors or its employee or its associates have not managed or co-managed the public offering of any company. Research Analyst or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation. The subject company was not a client of Research Analyst or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided. Research Analysts or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.
Full disclosures and disclaimers
ย
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.